FDA Finalizes Comparative Safety, Efficacy Requirement For New Opioids
Executive Summary
New opioids will need to provide a “significant advantage” over approved products under new requirements that treat opioids “differently” from other drug classes, outgoing Commissioner Gottlieb says.
You may also be interested in...
US FDA May Seek Legal Authority To Require Superiority Tests For Future Opioids
Commissioner Califf testifies at budget appropriations hearing that the agency may ask Congress to give it authority to require a new opioid drug application to show superiority to opioids on the market.
Breaking Up With Breakthrough: Trevena And Tonix Lose Designation, But Continue With Pivotal Plans
US FDA rescinds breakthrough designations for Tonix’ PTSD therapy Tonyma and Trevena’s novel pain drug Olinvo after clinical trial disappointments – and after identifying other regulatory pathways to market.
Dsuvia Approval May Be Followed By New Opioid Review Paradigm At FDA
US FDA Commissioner Gottlieb defended the decision to clear the controversial opioid in the agency’s press release on the approval, and announced a possible shift in how future opioid applications are reviewed.